

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

OMNIACTIVE HEALTH TECHNOLOGIES, INC.,
Petitioner,

v.

KEMIN INDUSTRIES, INC.
Patent Owner

Case No. IPR2017-00306
Patent No. 9,226,940

**JOINT MOTION TO TERMINATE PURSUANT TO
35 U.S.C. § 317 AND 37 C.F.R. § 42.74**

Pursuant to 35 U.S.C. § 317, 37 C.F.R. §§ 42.72 and 42.74, and the Board's authorization of February 7, 2017, Petitioner OmniActive Health Technologies, Inc. and Patent Owner Kemin Industries, Inc. jointly move to terminate the present *inter partes* review proceeding in light of the parties' settlement of their dispute insofar as it relates to U.S. Patent No. 9,226,940 ("the '940 patent"). The parties are filing, concurrently herewith, a true and complete copy of their written Settlement and License Agreement ("Settlement Agreement") (Confidential Exhibit 1032) in connection with this matter as required by the statute. The Settlement Agreement completely settles the parties' controversy and their dispute relating to the '940 patent as between Patent Owner and OmniActive Health Technologies, Inc., the Petitioner and real party-in-interest in the present proceeding, who was the plaintiff in the U.S. district court litigation captioned *OmniActive Health Technologies, Inc. v. Kemin Industries, Inc.*, 2016-cv-04988-CCC-JBC (D.N.J. filed August 15, 2016), and a respondent in an investigation before the U.S. International Trade Commission (ITC) captioned *Certain Food Supplements and Vitamins, Including Ocular Antioxidants and Components Thereof and Products Containing the Same*, Investigation No. 337-TA-1027, ("ITC Investigation"). In the ITC Investigation, the parties filed a Joint Motion to

Terminate the Investigation Based on Settlement on December 13, 2016 (Exhibit 1033),¹ and OmniActive filed a Notice of Voluntary Dismissal in the district court litigation on December 12, 2016 (Exhibit 1034). The ITC issued an Initial Determination to Terminate the Investigation Based on Settlement on December 28, 2016 (Exhibit 1035). The District Court issued an Order dismissing the civil action on December 16, 2016 (Exhibit 1036).

The parties further jointly certify that there are no other agreements or understandings, oral or written, between Patent Owner and Petitioner, including any collateral agreements, made in connection with, or in contemplation of, the termination of the present proceeding as set forth in 35 U.S.C. § 317(b).

The parties request that the Settlement Agreement (Confidential Exhibit 1030) be treated as business confidential information and kept separate from the file of the '940 patent. A joint request to treat the Settlement Agreement as business confidential information kept separate from the file of the involved patent pursuant to 35 U.S.C. § 317(b) is being filed concurrently herewith.

¹ Highly Confidential Exhibit B cited in Exhibit 1033 is the same document as the “Settlement Agreement” cited in this paper as Confidential Exhibit 1032.

Termination with Respect to Inter Partes Review Proceeding

A joint motion to terminate generally “must (1) include a brief explanation as to why termination is appropriate; (2) identify all parties in any related litigation involving the patents at issue; (3) identify any related proceedings currently before the Office, and (4) discuss specifically the current status of each such related litigation or proceeding with respect to each party to the litigation or proceeding.”

Heartland Tanning, Inc. v. Sunless, Inc., IPR2014-00018, Paper No. 26, at *2 (P.T.A.B. July 28, 2014). Each element is addressed below:

As for requirement (1), termination is appropriate in this proceeding because the parties have settled their dispute with respect to the '940 patent, and have agreed to terminate this *inter partes* review. The applicable statute, 35 U.S.C. § 317(a), provides that an *inter partes* review proceeding “shall be terminated with respect to any petitioner upon the joint request of the petitioner and the patent owner, unless the Office has decided the merits of the proceeding before the request for termination is filed.” In this case, the *inter partes* review has not yet been instituted. The Patent Owner’s Preliminary Response to the petition has not yet been filed, and the Office has made no decision on the merits. Moreover, as recognized by the rules of practice before the Board:

There are strong public policy reasons to favor settlement between the parties to a proceeding. The Board will be available to facilitate settlement discussions, and where appropriate, may require a

settlement discussion as part of the proceeding. The Board expects that a proceeding will terminate after the filing of a settlement agreement, unless the Board has already decided the merits of the proceeding.

Patent Office Trial Practice Guide, Fed. Register, Vol. 77, No. 157 at 48768 (Aug. 14, 2012). Moreover, no public interest or other factors militate against termination of this proceeding.

As for requirements (2) and (4), the table below identifies parties in district court litigations that involve or involved the '940 patent, and discusses the current status of these related litigations with respect to each party to the litigation. *See Heartland Tanning, Inc.*, Paper No. 26, at *2.

Case Caption	Current Status of Each Related Litigation With Respect to Each Party to the Litigation or Proceeding
<i>OmniActive Health Technologies, Inc. v. Kemin Industries, Inc.</i> , 2016-cv-04988-CCC-JBC, United States District Court for the District of New Jersey (filed on August 15, 2016)	Dismissed in view of Notice of Voluntary Dismissal by Order dated December 16, 2016.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.